{
    "eid": "2-s2.0-85141444075",
    "title": "Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmaceutical Science",
            "@code": "3003",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Lopinavir",
        "NONMEM",
        "Population pharmacokinetics",
        "Ritonavir",
        "Thai people living with HIV"
    ],
    "authors": [
        "Piyawat Chaivichacharn",
        "Anchalee Avihingsanon",
        "Sivaporn Gatechompol",
        "Sasiwimol Ubolyam",
        "Baralee Punyawudho"
    ],
    "citedby-count": 0,
    "ref-count": 56,
    "ref-list": [
        "Thailand National Guidelines on HIV/AIDS Diagnosis, treatment and Prevention 2020",
        "Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study)",
        "Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients",
        "Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients",
        "Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient",
        "Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens",
        "Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir",
        "Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations",
        "Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV",
        "A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults",
        "High variability of plasma drug concentrations in dual protease inhibitor regimens",
        "Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection",
        "Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection",
        "Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings",
        "A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients",
        "Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients",
        "Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients",
        "Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients",
        "Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults",
        "ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir",
        "Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients",
        "Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV",
        "Dosage optimization of efavirenz based on a population pharmacokinetic-pharmacogenetic model of HIV-infected patients in Thailand",
        "A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults",
        "Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial",
        "Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand",
        "Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients",
        "Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults",
        "Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily",
        "Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers",
        "Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin",
        "Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients",
        "Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies",
        "Handling data below the limit of quantification in mixed effect models",
        "Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling",
        "dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap",
        "An automated sampling importance resampling procedure for estimating parameter uncertainty",
        "Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models",
        "Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients",
        "ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results",
        "Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies",
        "Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naive patients",
        "Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays",
        "High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets",
        "Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers",
        "Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women",
        "The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes",
        "Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries",
        "Population pharmacokinetics of nevirapine in Thai HIV-infected patients",
        "Guidance for rifampin and midazolam dosing Protocols to study Intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and De-induction",
        "How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials",
        "Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets",
        "Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics",
        "Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients"
    ],
    "affiliation": [
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Research Council of Thailand"
    ]
}